Results 101 to 110 of about 121,794,009 (205)

The therapeutic efficacy of post-symptom 3,4-diaminopyridine treatment in cosmetic injection-induced botulism using a novel animal model

open access: yesBiomedical Technology
In recent years, the incidence of cosmetic injection-induced botulism has remarkably increased due to the frequent usage of botulinum neurotoxin type A (BoNT/A).
Ping He   +6 more
doaj   +1 more source

Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity

open access: yesToxins, 2011
The therapeutic potential of botulinum neurotoxin type A (BoNT/A) has recently been widely recognized. BoNT/A acts to silence synaptic transmission via specific proteolytic cleavage of an essential neuronal protein, SNAP25.
Bazbek Davletov   +9 more
doaj   +1 more source

The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells [PDF]

open access: yes, 1989
The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O.
M. Gratzl   +9 more
core   +1 more source

Botulinum Neurotoxin type A is effective to treat peripheral myoclonus post-amputation [PDF]

open access: yes, 2019
Peripheral myoclonus is a rare post-amputation complication characterized by sudden, brief and sometimes repetitive muscle contractions. BoNT-A prevents the release of the neurotransmitter acetylcholine at the axon ending of the neuromuscular junction ...
Boudier-Réverêt, Mathieu   +3 more
core  

Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life

open access: yes, 2009
OBJECTIVE: To investigate the hypothesis that the need for clean intermittent self-catheterization after botulinum neurotoxin type A injections is outweighed by the efficacy of this treatment, so that clean intermittent self-catheterization is not a ...
Panicker, Jalesh   +5 more
core  

Centrally mediated late motor recovery after botulinum toxin injection: Case reports and a review of current evidence

open access: yes, 2017
Objective: Botulinum neurotoxin is commonly utilized in neurorehabilitation as a treatment for focal spasticity. Clinical experience has yielded observations of late motor recovery after intramuscular injection of botulinum neurotoxin, that are not ...
M Mas   +5 more
core   +1 more source

Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals [PDF]

open access: yes, 2014
Botulinum neurotoxin type A1 (BoNTs/A1) and type B (BoNT/B) have been used for treating hyperactive muscle contractions. In the present study, we compared the effect of botulinum neurotoxin subtype A2 (6.5 mouse LD50 units A2 neurotoxin, A2NTX) and ...
Mukai, Yohei   +35 more
core  

Camelid single-domain antibody ciA-B5 recognizes light chain of botulinum neurotoxin type A by ELISA

open access: yes
Camelid single-domain antibody (VHH) ciA-B5 detects by ELISA the light chain (LC) of the botulinum neurotoxin type A (BoNT/A)
Dang, Tran Nhat Minh   +8 more
core   +1 more source

Complications After Botulinum Neurotoxin Type A and Dermal Filler Injections: Data From a Large Retrospective Cohort Study

open access: yesAesthetic Surgery Journal, 2022
Steenen, Serge A.   +3 more
openaire   +2 more sources

Lameness improvement in horses with distal tarsal pain after intra-articular injection of botulinum neurotoxin type A

open access: yesAmerican Journal of Veterinary Research
Abstract Objective To evaluate the effect of IA injections of botulinum toxin type A (BoNT-A) in horses with chronic, naturally occurring distal tarsal osteoarthritis. Methods 9 horses were selected after physical and radiographic assessments. Horses also underwent an objective lameness examination and were included if they had a hindlimb impact ...
Antônio A. Beck   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy